BRAF and melanoma: Although inhibitors of the MAPK pathway remain a common therapeutic strategy in malignant melanoma, many trials have focused on patients harboring BRAF-V600E mutations, without similar enrollment opportunities for patients with BRAF fusion-positive tumors.